Literature DB >> 20041760

G2-phase chromosomal radiosensitivity of primary fibroblasts from hereditary retinoblastoma family members and some apparently normal controls.

Paul F Wilson1, Hatsumi Nagasawa, Markus M Fitzek, John B Little, Joel S Bedford.   

Abstract

We previously described an enhanced sensitivity for cell killing and gamma-H2AX focus induction after both high-dose-rate and continuous low-dose-rate gamma irradiation in 14 primary fibroblast strains derived from hereditary-type retinoblastoma family members (both affected RB1(+/-) probands and unaffected RB1(+/+) parents). Here we present G(2)-phase chromosomal radiosensitivity assay data for primary fibroblasts derived from these RB family members and five Coriell cell bank controls (four apparently normal individuals and one bilateral RB patient). The RB family members and two normal Coriell strains had significantly higher ( approximately 1.5-fold, P < 0.05) chromatid-type aberration frequencies in the first postirradiation mitosis after doses of 50 cGy and 1 Gy of (137)Cs gamma radiation compared to the remaining Coriell strains. The induction of chromatid-type aberrations by high-dose-rate G(2)-phase gamma irradiation is significantly correlated to the proliferative ability of these cells exposed to continuous low-dose-rate gamma irradiation (reported in Wilson et al., Radiat. Res. 169, 483-494, 2008). Our results suggest that these moderately radiosensitive individuals may harbor hypomorphic genetic variants in genomic maintenance and/or DNA repair genes or may carry epigenetic changes involving genes that more broadly modulate such systems, including G(2)-phase-specific DNA damage responses.

Entities:  

Mesh:

Year:  2010        PMID: 20041760      PMCID: PMC2819004          DOI: 10.1667/RR1943.1

Source DB:  PubMed          Journal:  Radiat Res        ISSN: 0033-7587            Impact factor:   2.841


  61 in total

1.  Heritability of cellular radiosensitivity: a marker of low-penetrance predisposition genes in breast cancer?

Authors:  S A Roberts; A R Spreadborough; B Bulman; J B Barber; D G Evans; D Scott
Journal:  Am J Hum Genet       Date:  1999-09       Impact factor: 11.025

2.  Influence of double-strand-break repair pathways on radiosensitivity throughout the cell cycle in CHO cells.

Authors:  John M Hinz; N Alice Yamada; Edmund P Salazar; Robert S Tebbs; Larry H Thompson
Journal:  DNA Repair (Amst)       Date:  2005-07-12

3.  Inherited susceptibility to bleomycin-induced chromatid breaks in cultured peripheral blood lymphocytes.

Authors:  J Cloos; E J Nieuwenhuis; D I Boomsma; D J Kuik; M L van der Sterre; F Arwert; G B Snow; B J Braakhuis
Journal:  J Natl Cancer Inst       Date:  1999-07-07       Impact factor: 13.506

4.  Mutagen sensitivity has high heritability: evidence from a twin study.

Authors:  Xifeng Wu; Margaret R Spitz; Christopher I Amos; Jie Lin; Lina Shao; Jian Gu; Mariza de Andrade; Neal L Benowitz; Peter G Shields; Gary E Swan
Journal:  Cancer Res       Date:  2006-06-15       Impact factor: 12.701

5.  Chromosomal radiosensitivity in G2-phase lymphocytes as an indicator of cancer predisposition.

Authors:  D Scott; A R Spreadborough; L A Jones; S A Roberts; C J Moore
Journal:  Radiat Res       Date:  1996-01       Impact factor: 2.841

Review 6.  Human population studies with cytogenetic biomarkers: review of the literature and future prospectives.

Authors:  Stefano Bonassi; Donatella Ugolini; Micheline Kirsch-Volders; Ulf Strömberg; Roel Vermeulen; James D Tucker
Journal:  Environ Mol Mutagen       Date:  2005 Mar-Apr       Impact factor: 3.216

7.  Cell death mechanisms associated with G2 radiosensitivity in patients with prostate cancer and benign prostatic hyperplasia.

Authors:  Orla Howe; Kiaran O'Malley; Martin Lavin; Robert A Gardner; Colin Seymour; Fiona Lyng; David Mulvin; David M Quinlan; Carmel Mothersill
Journal:  Radiat Res       Date:  2005-11       Impact factor: 2.841

8.  Increased chromosomal radiosensitivity in breast cancer patients: a comparison of two assays.

Authors:  D Scott; J B Barber; A R Spreadborough; W Burrill; S A Roberts
Journal:  Int J Radiat Biol       Date:  1999-01       Impact factor: 2.694

9.  Cytogenetic responses to G2 phase x-irradiation of cells from retinoblastoma patients.

Authors:  K K Sanford; R Parshad; F M Price; R E Tarone; W F Benedict
Journal:  Cancer Genet Cytogenet       Date:  1996-05

10.  Megabase chromatin domains involved in DNA double-strand breaks in vivo.

Authors:  E P Rogakou; C Boon; C Redon; W M Bonner
Journal:  J Cell Biol       Date:  1999-09-06       Impact factor: 10.539

View more
  6 in total

1.  Influence of homologous recombinational repair on cell survival and chromosomal aberration induction during the cell cycle in gamma-irradiated CHO cells.

Authors:  Paul F Wilson; John M Hinz; Salustra S Urbin; Peter B Nham; Larry H Thompson
Journal:  DNA Repair (Amst)       Date:  2010-07-01

Review 2.  Variation in base excision repair capacity.

Authors:  David M Wilson; Daemyung Kim; Brian R Berquist; Alice J Sigurdson
Journal:  Mutat Res       Date:  2010-12-15       Impact factor: 2.433

3.  Epidemiology and Rb1 gene of retinoblastoma.

Authors:  Jun Yun; Yang Li; Chang-Tai Xu; Bo-Rong Pan
Journal:  Int J Ophthalmol       Date:  2011-02-18       Impact factor: 1.779

4.  Genetic predisposition to radiation-related cancer and potential implications for risk assessment.

Authors:  A J Sigurdson; D O Stram
Journal:  Ann ICRP       Date:  2012-08-22

5.  Germline genetic biomarkers to stratify patients for personalized radiation treatment.

Authors:  Ida Deichaite; Austin Hopper; Hannah Carter; Vitali Moiseenko; Lena Krockenberger; Timothy J Sears; Leisa Sutton; Xenia Ray; Andrew Sharabi; Ami Navon; Parag Sanghvi
Journal:  J Transl Med       Date:  2022-08-12       Impact factor: 8.440

6.  Exploiting DNA repair pathways for tumor sensitization, mitigation of resistance, and normal tissue protection in radiotherapy.

Authors:  Jac A Nickoloff; Lynn Taylor; Neelam Sharma; Takamitsu A Kato
Journal:  Cancer Drug Resist       Date:  2021-06-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.